Cargando…

Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors

OBJECTIVE: FMS-like tyrosine kinase 3 (FLT3) is an attractive therapeutic target in acute myeloid leukemia. Unfortunately, secondary FLT3 mutations that developed resistance to inhibitors have become a severe problem. Specifically, ASP-835 (D835F/H/V/Y) mutant within the activation loop of FLT3 is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhiwei, Hu, Baichun, An, Yu, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979743/ https://www.ncbi.nlm.nih.gov/pubmed/35387260 http://dx.doi.org/10.1155/2022/3720026

Ejemplares similares

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)

Development of a highly sensitive method for detection of FLT3D835Y
por: Guo, Yao, et al.
Publicado: (2020)

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach
por: Al-Subaie, Abeer M., et al.
Publicado: (2021)

Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans
por: Ayatollahi, Hossein, et al.
Publicado: (2015)

FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance
por: Elyamany, Ghaleb, et al.
Publicado: (2014)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm
por: Cianga, Vlad Andrei, et al.
Publicado: (2021)

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
por: Marhäll, Alissa, et al.
Publicado: (2018)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

EXM 83.5
Publicado: (1983)

PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia
por: Jang, Seong Hun, et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
por: Hatırnaz Ng, Özden, et al.
Publicado: (2022)

Data acquisition system for E-835 silicon detector
por: Musico, P, et al.
Publicado: (1997)

A Silicon Pad Detector for E-835 experiment at Fermilab
por: Buzzo, A, et al.
Publicado: (1996)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Insights Into the Resistance Mechanisms of Inhibitors to FLT3 F691L Mutation via an Integrated Computational Approach
por: Sun, Yunfeng, et al.
Publicado: (2019)

Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients
por: PASSAMANO, LUIGIA, et al.
Publicado: (2012)

835. Comparison of the outcomes of patients with KPC and NDM-1-producing Enterobacteriaceae
por: Seo, Hyeonji, et al.
Publicado: (2020)

P835: GENETIC BACKGROUND AND CLINICAL CHARACTERISTICS OF CONGENITAL NEUTROPENIAS IN ISRAEL
por: Steinberg-Shemer, O., et al.
Publicado: (2022)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
por: Long, Xiang, et al.
Publicado: (2020)

Induction of Autophagy in the Striatum and Hypothalamus of Mice after 835 MHz Radiofrequency Exposure
por: Kim, Ju Hwan, et al.
Publicado: (2016)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Effect of Ginseng on Calretinin Expression in Mouse Hippocampus Following Exposure to 835 MHz Radiofrequency
por: Aryal, Bijay, et al.
Publicado: (2011)

835 Comparison of the Clinical Characteristics and Outcomes of Klebsiella pneumoniae Meningitis and Streptococcus pneumoniae Meningitis
por: Jung, Jiwon, et al.
Publicado: (2014)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
por: Xiao, Xinhua, et al.
Publicado: (2023)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
por: Weisberg, Ellen, et al.
Publicado: (2011)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lal8rd6iau6frb7vh3iohqbhef